Biogen Inc. (BIIB)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Biogen Inc. (BIIB) trades at $177.34 with AI Score 59/100 (Hold). Biogen Inc. is a biotechnology company focused on developing therapies for neurological and neurodegenerative diseases. Market cap: $26.03B, Sector: Healthcare.
Last analyzed: Feb 9, 2026Biogen Inc. (BIIB) Healthcare & Pipeline Overview
Biogen pioneers therapies for neurological and neurodegenerative diseases, holding a strong position in multiple sclerosis and spinal muscular atrophy treatments, while aggressively pursuing Alzheimer's solutions and biosimilar opportunities, making it a compelling investment in the growing neurology market with a $29.51B market cap.
Investment Thesis
Biogen represents a notable research candidate due to its established presence in the neurology market and its pursuit of innovative therapies. The company's MS franchise, while facing competition, generates consistent revenue. SPINRAZA continues to be a key revenue driver in spinal muscular atrophy. The development and potential commercial success of Lecanemab for Alzheimer's disease could be a significant catalyst. Biogen's biosimilar portfolio offers growth potential by providing cost-effective alternatives to branded biologics. With a P/E ratio of 22.82, Biogen's valuation reflects its earnings potential. Key value drivers include successful pipeline development, strategic collaborations, and effective cost management.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $29.51B reflects Biogen's significant presence in the biotechnology industry.
- P/E Ratio of 22.82 indicates the price investors are willing to pay for each dollar of Biogen's earnings.
- Profit Margin of 13.2% demonstrates Biogen's ability to generate profit from its revenue.
- Gross Margin of 70.5% highlights Biogen's efficient production and pricing strategies.
- Beta of 0.16 suggests that Biogen's stock price is less volatile than the overall market.
Competitors & Peers
Strengths
- Strong portfolio of MS drugs.
- SPINRAZA for spinal muscular atrophy is a key revenue driver.
- Expertise in biosimilar development.
- Established collaborations with other pharmaceutical companies.
Weaknesses
- Dependence on MS franchise, facing increasing competition.
- Past controversies surrounding ADUHELM's efficacy and pricing.
- High research and development costs.
- Regulatory hurdles for new drug approvals.
Catalysts
- Regulatory decisions on pipeline candidates, particularly Lecanemab for Alzheimer's disease.
- Clinical trial results for new therapies in development.
- Expansion of biosimilar market share.
- Strategic partnerships and acquisitions to expand product portfolio.
Risks
- Failure of clinical trials for pipeline candidates.
- Regulatory setbacks for new drug approvals.
- Increasing competition in the MS market.
- Pricing pressures from healthcare payers.
- Patent challenges to key drugs.
Growth Opportunities
- Alzheimer's Disease Therapies: Biogen's Lecanemab represents a significant growth opportunity in the Alzheimer's disease market. The market for Alzheimer's treatments is projected to reach billions of dollars annually as the global population ages. Successful commercialization of Lecanemab could generate substantial revenue for Biogen, addressing a critical unmet need. Timeline for significant revenue impact is expected within the next 2-3 years, pending regulatory approvals and market adoption.
- Biosimilar Expansion: Biogen's biosimilar portfolio, including BENEPALI, IMRALDI, and FLIXABI, offers a growth avenue by providing cost-effective alternatives to branded biologics. The global biosimilars market is expanding rapidly, driven by increasing healthcare costs and patent expirations of blockbuster drugs. Biogen's expertise in biologics manufacturing gives it a competitive advantage. This growth is ongoing and expected to contribute steadily to revenue.
- Neuromuscular Disorder Pipeline: Biogen is developing therapies for neuromuscular disorders, including BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110. These programs target diseases with limited treatment options, representing a significant unmet need. Successful development and commercialization of these therapies could drive substantial growth. Clinical trial results and potential regulatory submissions are expected over the next 3-5 years.
- Strategic Collaborations: Biogen's collaborations with companies like Eisai, Genentech, and Ionis Pharmaceuticals enhance its research and development capabilities. These partnerships provide access to novel technologies and therapeutic candidates, accelerating the development of new treatments. Ongoing collaborations are expected to yield new product opportunities and revenue streams over the long term.
- Expansion in Neuroimmunology: Biogen is developing therapies for neuroimmunology, including BIIB135, BIIB061, BIIB091, and BIIB107. The neuroimmunology market is growing due to increased understanding of the role of the immune system in neurological diseases. Successful development of these therapies could expand Biogen's presence in this growing market. Clinical trial progress and potential product launches are anticipated within the next 4-6 years.
Opportunities
- Potential success of Lecanemab in Alzheimer's disease.
- Expansion of biosimilar portfolio.
- Development of new therapies for neuromuscular disorders.
- Strategic acquisitions and partnerships.
Threats
- Increasing competition in the MS market.
- Patent expirations on key drugs.
- Unsuccessful clinical trials for pipeline candidates.
- Pricing pressures from healthcare payers.
Competitive Advantages
- Strong intellectual property protection for its innovative therapies.
- Established brand recognition and reputation in the neurology market.
- Expertise in biologics manufacturing and biosimilar development.
- Extensive research and development capabilities.
- Strategic collaborations with leading biotechnology and pharmaceutical companies.
About BIIB
Founded in 1978 and headquartered in Cambridge, Massachusetts, Biogen Inc. is a global biotechnology leader dedicated to discovering, developing, manufacturing, and delivering innovative therapies for neurological and neurodegenerative diseases. The company's initial focus was on recombinant DNA technology, evolving into a powerhouse in neurology. Biogen's portfolio includes established treatments for multiple sclerosis (MS) such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI, as well as SPINRAZA for spinal muscular atrophy. The company also markets FUMADERM for plaque psoriasis. Biogen has expanded its offerings to include biosimilars like BENEPALI (etanercept), IMRALDI (adalimumab), and FLIXABI (infliximab), referencing established brands like ENBREL, HUMIRA, and REMICADE, respectively. Biogen's pipeline includes potential treatments for Alzheimer's disease (Aducanumab, Lecanemab), Parkinson's disease, and other neurological disorders. Collaborations with companies like Eisai, Genentech, and Ionis Pharmaceuticals enhance Biogen's research and development capabilities. With a profit margin of 13.2% and a gross margin of 70.5%, Biogen balances innovation with financial discipline.
What They Do
- Discovers and develops therapies for neurological diseases.
- Manufactures and delivers treatments for multiple sclerosis (MS).
- Offers therapies for spinal muscular atrophy (SMA).
- Develops biosimilars as cost-effective alternatives to branded biologics.
- Researches and develops treatments for Alzheimer's disease and dementia.
- Provides therapies for non-Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL).
- Develops treatments for neuromuscular disorders.
- Pursues therapies for neuroimmunology and related diseases.
Business Model
- Develops and patents novel pharmaceutical products.
- Generates revenue through the sale of prescription drugs.
- Partners with other companies for research, development, and commercialization.
- Manufactures and sells biosimilars of established biologic drugs.
Industry Context
Biogen operates in the competitive pharmaceutical industry, specifically within the neurology and neurodegenerative disease space. The market is characterized by high research and development costs, stringent regulatory requirements, and intense competition from companies developing novel therapies. The industry is experiencing growth driven by an aging population and increasing prevalence of neurological disorders. Key trends include the development of biosimilars, personalized medicine, and gene therapies. Competitors like INCY and GMAB are also focused on innovative therapies. Biogen's established presence and diverse pipeline position it to capitalize on these trends.
Key Customers
- Patients suffering from neurological and neurodegenerative diseases.
- Hospitals and clinics that administer Biogen's therapies.
- Pharmacies that dispense Biogen's medications.
- Healthcare providers who prescribe Biogen's treatments.
Financials
Chart & Info
Biogen Inc. (BIIB) stock price: $177.34 (+1.88, +0.99%)
Latest News
-
Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy
benzinga · Apr 3, 2026
-
Stocks Surge on Signs the US and Iran Seek to End War
Barchart · Mar 31, 2026
-
These Stocks Are Today’s Movers: CoreWeave, Microsoft, McCormick, Constellation, Biogen, Marvell, and More
Barrons.com · Mar 31, 2026
-
Trump Signals Iran Exit, S&P 500 Heads For Worst Month Since September 2022: What's Moving The Market On Tuesday?
benzinga · Mar 31, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BIIB.
Price Targets
Consensus target: $205.90
MoonshotScore
What does this score mean?
The MoonshotScore rates BIIB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy
Stocks Surge on Signs the US and Iran Seek to End War
These Stocks Are Today’s Movers: CoreWeave, Microsoft, McCormick, Constellation, Biogen, Marvell, and More
Trump Signals Iran Exit, S&P 500 Heads For Worst Month Since September 2022: What's Moving The Market On Tuesday?
Latest Biogen Inc. Analysis
BIIB Healthcare Stock FAQ
What does Biogen Inc. do?
Biogen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers therapies for neurological and neurodegenerative diseases. Its core business revolves around creating and commercializing treatments for conditions like multiple sclerosis (MS), spinal muscular atrophy (SMA), and Alzheimer's disease. The company also develops and markets biosimilars, which are cost-effective alternatives to branded biologic drugs. Biogen collaborates with other pharmaceutical companies to expand its research and development efforts, aiming to address unmet medical needs in neurology.
Is BIIB stock worth researching?
BIIB stock presents a mixed investment case. Its established MS franchise and SPINRAZA revenue provide a stable base, but face increasing competition. The potential success of Lecanemab in Alzheimer's disease could be a significant catalyst, but carries regulatory and market adoption risks. Biogen's P/E ratio of 22.82 reflects its earnings potential, but investors may want to evaluate the risks associated with pipeline development and competition. A balanced analysis of growth prospects and potential setbacks is crucial before investing.
What are the main risks for BIIB?
Biogen faces several key risks. Increasing competition in the MS market could erode its market share. Unsuccessful clinical trials for pipeline candidates would negatively impact future growth. Regulatory setbacks for new drug approvals could delay or prevent product launches. Pricing pressures from healthcare payers could reduce revenue and profitability. Additionally, patent expirations on key drugs could lead to generic competition. These risks require careful monitoring and mitigation strategies.
What are the key factors to evaluate for BIIB?
Biogen Inc. (BIIB) currently holds an AI score of 59/100, indicating moderate score. The stock trades at a P/E of 21.7x, near the S&P 500 average (~20-25x). Analysts target $205.90 (+16% from $177.34). Key strength: Strong portfolio of MS drugs. Primary risk to monitor: Failure of clinical trials for pipeline candidates. This is not financial advice.
How frequently does BIIB data refresh on this page?
BIIB prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BIIB's recent stock price performance?
Recent price movement in Biogen Inc. (BIIB) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $205.90 implies 16% upside from here. Notable catalyst: Strong portfolio of MS drugs. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BIIB overvalued or undervalued right now?
Determining whether Biogen Inc. (BIIB) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 21.7. Analysts target $205.90 (+16% from current price), suggesting analysts see upside potential. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BIIB?
Before investing in Biogen Inc. (BIIB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Stock data pending update.